People with HIV who are 18 and older and who have become resistant to more than one HIV medication will take BMS-663068 (an experimental HIV attachment inhibitor) or Reyataz for up to 96 weeks. Everyone will also take Isentress and Viread. Open for enrollment.

People with HIV who are 18 and older and who have not taken HIV meds will take either Cenicriviroc (an experimental CCR5 inhibitor) or Sustiva for a year. Everyone will also take Truvada.
Open for enrollment.

People with HIV who are 18 and older and who have not taken HIV meds will take either Selzentry or Truvada for 22 months. Everyone will also take Prezista with Norvir.
Open for enrollment.

Trial #1: People aged 18 to 70 who have hepatitis C virus and HIV will take BI 201335 (an experimental HCV protease inhibitor) with peg-interferon and ribavirin for 12-48 weeks.  
Open for enrollment.

Trial #2: People aged 18 to 70 who have hepatitis C virus but not HIV, and who have not taken interferon, will take
BI 201335 (an experimental HCV protease inhibitor) with peg-interferon and ribavirin for 12-48 weeks.
Closed to enrollment.

People who are HIV negative will receive four weekly injections of ibalizumab (a monoclonal antibody) to study its safety and effect on the immune system.
Closed to enrollment.

People 18 and older who have persistent diarrhea will first take crofelemer or placebo tablets for 6 weeks. Then everyone will take crofelemer for 5 months.
Closed to enrollment.

For additional information we invite you to contact the research department at research@acria.org or on (212) 924-3934, ext. 100.